Press

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Oct 20 • 2 min read

Quick Take: The Company expects to hold a Research & Development event to review these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media Cybin Inc. (NEO:CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 74th pre-clinical study as it…

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

Oct 19 • 5 min read

Quick Take: The partnership will Create Patented Products for the Treatment of Neuroinflammatory Disorders Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, and Mycrodose Therapeutics, a US pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds,…

Clearmind Medicine Partners With Clinipace to Commence Processes Towards FDA Approval

Oct 18 • 3 min read

Quick Take: The Regulatory affairs and CRO will oversee the Company’s efforts to secure an IND review of MEAI as a potential treatment for Alcohol Use Disorder and binge drinking Clearmind Medicine Inc. (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health…

Levitee Labs Signs Letter of Intent to Acquire Calgary Addiction and Compounding Pharmacy

Oct 15 • 3 min read

Quick Take: The pharmacy will be used as an initial base for the production and distribution of pharmaceutical products for Levitee Labs, which will include pain and depression management products such as ketamine. Levitee Labs Inc. (CSE: LVT), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, has signed a letter of intent to acquire 51% of the issued…

Tryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETF

Oct 14 • 2 min read

Quick Take: The Fund is actively trading and focuses on companies that devote a majority of assets to psychedelic drug development. Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today its inclusion in the AdvisorShares Psychedelics ETF, currently trading under the ticker symbol…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438